Treatment of Dyslipidemia in Chronic Renal Failure?

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Dyslipidemia in end-stage renal disease is a common problem and may contribute to the high rates of morbidity and mortality in this population. Recent studies indicate that defective lipolysis is a major factor in the development of this disorder which is characterized by increased levels of very-low-density-lipoprotein remnant particles, hypertriglyceridemia and occasionally hypercholesterolemia. There are no prospective long-term studies on the effect of lipid-lowering treatment on morbidity and mortality related to dyslipidemia. Therefore, at present pharmacologic treatment of hyperlipidemia should be undertaken in patients with severe hypertriglyceridemia (> 500 mg/dl) or hypercholesterolemia (LDL > 130 mg/dl) who are at high risk for coronary artery disease. This review discusses the pathogenesis of dyslipidemia, common clinical patterns of hyperlipidemia and various nonpharmacologic and pharmacologic treatment options.

Original languageEnglish (US)
Pages (from-to)75-82
Number of pages8
JournalBlood Purification
Issue number1
StatePublished - Jan 1 1996


  • Atherosclerosis
  • Cardiovascular complications
  • Dyslipidemia
  • End-stage renal disease
  • Lipid-lowering treatment

ASJC Scopus subject areas

  • Hematology
  • Nephrology


Dive into the research topics of 'Treatment of Dyslipidemia in Chronic Renal Failure?'. Together they form a unique fingerprint.

Cite this